Cybin Inc. (AMEX:CYBN) shares traded 0.65% higher at $0.31 on Wall Street last session.
In accordance with the data, 6 analysts cover Cybin Inc. (AMEX:CYBN). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $10.00 and a low of $1.12, we find $4.06. Given the previous closing price of $0.31, this indicates a potential upside of 1209.68 percent. CYBN stock price is now -24.73% away from the 50-day moving average and -49.66% away from the 200-day moving average. The market capitalization of the company currently stands at $81.12M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
It has been rated a hold by 0 analysts and a buy by 6. Brokers who have rated the stock have averaged $4.74 as their price target over the next twelve months.
.
Insiders disposed of 20,000 shares of company stock worth roughly $6200.0 over the past 1 year. A total of 20.22% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in CYBN stock. A new stake in Cybin Inc. shares was purchased by CANTOR FITZGERALD, L. P. during the first quarter worth $93,000. CERITY PARTNERS LLC invested $18,000 in shares of CYBN during the first quarter. In the first quarter, MILLENNIUM MANAGEMENT LLC acquired a new stake in Cybin Inc. valued at approximately $18,000. VIRTU FINANCIAL LLC acquired a new stake in CYBN for approximately $14,000. NADLER FINANCIAL GROUP, INC. purchased a new stake in CYBN valued at around $14,000 in the second quarter. In total, there are 65 active investors with 10.23% ownership of the company’s stock.
Cybin Inc. (AMEX: CYBN) opened at $0.2910 on Tuesday. During the past 12 months, Cybin Inc. has had a low of $0.26 and a high of $1.29. The fifty day moving average price for CYBN is $0.4118 and a two-hundred day moving average price translates $0.6158 for the stock.
The latest earnings results from Cybin Inc. (AMEX: CYBN) was released for Jun, 2022.
Cybin Inc.(CYBN) Company Profile
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company’s development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.
